NCT05878522View on ClinicalTrials.gov

A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

October 30, 2023

Study Completion Date

October 30, 2023

Conditions
Healthy
Interventions
DRUG

sisunatovir

6 capsules administered Q12 hours for 5 doses

DRUG

placebo

6 capsules administered Q12 hours for 5 doses

DRUG

moxifloxacin

6 capsules of placebo administered Q12 hours for 4 doses, followed by a single tablet of moxifloxacin

DRUG

sisunatovir

7 capsules administered Q12 hours for 5 doses

Trial Locations (1)

06511

New Haven Clinical Research Unit, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05878522 - A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants. | Biotech Hunter | Biotech Hunter